Pharmaceutical Technology Europe
A new year, all things being equal, is a time of looking to the future with positive intent and traditional bonhomie. At the very least, it suggests new beginnings. As we enter 2009, however, the world is moving into a major recession and things are far from equal.
As an industry, biopharma is relatively well protected relying as it does on the collective, rather than individual, purse. But the winds of change are fairly fierce. Even those who have always considered they have a job and a house for life are feeling a lot less secure as they enter 2009 than they did going into 2008. Those who still have jobs may well be working for new owners. Those who no longer have a regular wage are doubtless plotting a whole new way of life.
Jacky Law
So, in an effort to restore some of the feel-good factor that traditionally accompanies New Year's Day, and as someone who hasn't had a regular wage for years, I want to offer some reasons for optimism:
Which brings us back to the subject of new beginnings at the start of 2009. A keen survival instinct latches onto anything that offers hope and works with that to create the new beginnings for themselves and their families. That hope may come from operating in a growth area or in a company large enough to withstand the storm. But it may also come from something much more fundamental that applies even to the most dispensable: that necessity is the mother of invention, no one or nothing changes unless it has to. I know; I have been freelance for years. I also know that not having a job is not the same as being idle.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.